Category: Press Release - Page 94 - Psychedelic Alpha

Read more about the article Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Post published:October 27, 2021
Post category:Press Release

Read more about the article Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin

Post published:October 27, 2021
Post category:Press Release

Read more about the article World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

Post published:October 27, 2021
Post category:Press Release

Read more about the article Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Post published:October 27, 2021
Post category:Press Release

Read more about the article Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Post published:October 26, 2021
Post category:Press Release

Read more about the article Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Post published:October 26, 2021
Post category:Press Release

Read more about the article MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Post published:October 26, 2021
Post category:Press Release

Read more about the article MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

Post published:October 26, 2021
Post category:Press Release

Read more about the article HAVN Life Announces Departure of Rick Brar as Director

HAVN Life Announces Departure of Rick Brar as Director

Post published:October 25, 2021
Post category:Press Release

Read more about the article Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Post published:October 25, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.